-
Je něco špatně v tomto záznamu ?
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
B. Ljungberg, L. Albiges, Y. Abu-Ghanem, K. Bensalah, S. Dabestani, S. Fernández-Pello, RH. Giles, F. Hofmann, M. Hora, MA. Kuczyk, T. Kuusk, TB. Lam, L. Marconi, AS. Merseburger, T. Powles, M. Staehler, R. Tahbaz, A. Volpe, A. Bex,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, směrnice pro lékařskou praxi
- MeSH
- adjuvantní chemoterapie MeSH
- cílená molekulární terapie MeSH
- karcinom z renálních buněk diagnóza sekundární terapie MeSH
- lidé MeSH
- nádory ledvin diagnóza patologie terapie MeSH
- nefrektomie metody MeSH
- pozorné vyčkávání MeSH
- protinádorové látky imunologicky aktivní terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- směrnice pro lékařskou praxi MeSH
CONTEXT: The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. OBJECTIVE: To provide an updated RCC guideline based on standardised methodology including systematic reviews, which is robust, transparent, reproducible, and reliable. EVIDENCE ACQUISITION: For the 2019 update, evidence synthesis was undertaken based on a comprehensive and structured literature assessment for new and relevant data. Where necessary, formal systematic reviews adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were undertaken. Relevant databases (Medline, Cochrane Libraries, trial registries, conference proceedings) were searched until June 2018, including randomised controlled trials (RCTs) and retrospective or controlled studies with a comparator arm, systematic reviews, and meta-analyses. Where relevant, risk of bias (RoB) assessment, and qualitative and quantitative syntheses of the evidence were performed. The remaining sections of the document were updated following a structured literature assessment. Clinical practice recommendations were developed and issued based on the modified GRADE framework. EVIDENCE SYNTHESIS: All chapters of the RCC guidelines were updated based on a structured literature assessment, for prioritised topics based on the availability of robust data. For RCTs, RoB was low across studies. For most non-RCTs, clinical and methodological heterogeneity prevented pooling of data. The majority of included studies were retrospective with matched or unmatched cohorts, based on single- or multi-institutional data or national registries. The exception was for the treatment of metastatic RCC, for which there were several large RCTs, resulting in recommendations based on higher levels of evidence. CONCLUSIONS: The 2019 RCC guidelines have been updated by the multidisciplinary panel using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019. PATIENT SUMMARY: The European Association of Urology Renal Cell Carcinoma Guideline Panel has thoroughly evaluated the available research data on kidney cancer to establish international standards for the care of kidney cancer patients.
Academic Urology Unit University of Aberdeen Aberdeen UK
Department of Cancer Medicine Gustave Roussy Université Paris Saclay Villejuif France
Department of Clinical Sciences Lund Skåne University Hospital Lund Sweden
Department of Surgical and Perioperative Sciences Urology and Andrology Umeå University Umeå Sweden
Department of Urology Aberdeen Royal Infirmary Aberdeen UK
Department of Urology and Urologic Oncology Hannover Medical School Hannover Germany
Department of Urology Cabueñes University Hospital Gijón Spain
Department of Urology Chaim Sheba Medical Center Tel Hashomer Ramat Gan Israel
Department of Urology Coimbra University Hospital Coimbra Portugal
Department of Urology Ludwig Maximilians University Munich Germany
Department of Urology Royal Free Hospital Pond Street London UK
Department of Urology Sunderby Hospital Sunderby Sweden
Department of Urology University Hospital Hamburg Eppendorf Hamburg Germany
Department of Urology University Hospital Schleswig Holstein Lübeck Germany
Department of Urology University of Rennes Rennes France
Division of Urology Maggiore della Carità Hospital University of Eastern Piedmont Novara Italy
The Royal Free London NHS Foundation Trust London UK
The Royal Free NHS Trust and Barts Cancer Institute Queen Mary University of London London UK
UCL Division of Surgery and Interventional Science London UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19044968
- 003
- CZ-PrNML
- 005
- 20200114083311.0
- 007
- ta
- 008
- 200109s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2019.02.011 $2 doi
- 035 __
- $a (PubMed)30803729
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Ljungberg, Börje $u Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden. Electronic address: borje.ljungberg@umu.se.
- 245 10
- $a European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update / $c B. Ljungberg, L. Albiges, Y. Abu-Ghanem, K. Bensalah, S. Dabestani, S. Fernández-Pello, RH. Giles, F. Hofmann, M. Hora, MA. Kuczyk, T. Kuusk, TB. Lam, L. Marconi, AS. Merseburger, T. Powles, M. Staehler, R. Tahbaz, A. Volpe, A. Bex,
- 520 9_
- $a CONTEXT: The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. OBJECTIVE: To provide an updated RCC guideline based on standardised methodology including systematic reviews, which is robust, transparent, reproducible, and reliable. EVIDENCE ACQUISITION: For the 2019 update, evidence synthesis was undertaken based on a comprehensive and structured literature assessment for new and relevant data. Where necessary, formal systematic reviews adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were undertaken. Relevant databases (Medline, Cochrane Libraries, trial registries, conference proceedings) were searched until June 2018, including randomised controlled trials (RCTs) and retrospective or controlled studies with a comparator arm, systematic reviews, and meta-analyses. Where relevant, risk of bias (RoB) assessment, and qualitative and quantitative syntheses of the evidence were performed. The remaining sections of the document were updated following a structured literature assessment. Clinical practice recommendations were developed and issued based on the modified GRADE framework. EVIDENCE SYNTHESIS: All chapters of the RCC guidelines were updated based on a structured literature assessment, for prioritised topics based on the availability of robust data. For RCTs, RoB was low across studies. For most non-RCTs, clinical and methodological heterogeneity prevented pooling of data. The majority of included studies were retrospective with matched or unmatched cohorts, based on single- or multi-institutional data or national registries. The exception was for the treatment of metastatic RCC, for which there were several large RCTs, resulting in recommendations based on higher levels of evidence. CONCLUSIONS: The 2019 RCC guidelines have been updated by the multidisciplinary panel using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019. PATIENT SUMMARY: The European Association of Urology Renal Cell Carcinoma Guideline Panel has thoroughly evaluated the available research data on kidney cancer to establish international standards for the care of kidney cancer patients.
- 650 _2
- $a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
- 650 _2
- $a karcinom z renálních buněk $x diagnóza $x sekundární $x terapie $7 D002292
- 650 _2
- $a adjuvantní chemoterapie $7 D017024
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory ledvin $x diagnóza $x patologie $x terapie $7 D007680
- 650 _2
- $a cílená molekulární terapie $7 D058990
- 650 _2
- $a nefrektomie $x metody $7 D009392
- 650 _2
- $a pozorné vyčkávání $7 D057832
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 700 1_
- $a Albiges, Laurance $u Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
- 700 1_
- $a Abu-Ghanem, Yasmin $u Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
- 700 1_
- $a Bensalah, Karim $u Department of Urology, University of Rennes, Rennes, France.
- 700 1_
- $a Dabestani, Saeed $u Department of Clinical Sciences Lund, Skåne University Hospital, Lund, Sweden.
- 700 1_
- $a Fernández-Pello, Sergio $u Department of Urology, Cabueñes University Hospital, Gijón, Spain.
- 700 1_
- $a Giles, Rachel H $u Department of Nephrology and Hypertension, Patient Advocate International Kidney Cancer Coalition (IKCC), University Medical Center Utrecht, Utrecht, The Netherlands.
- 700 1_
- $a Hofmann, Fabian $u Department of Urology, Sunderby Hospital, Sunderby, Sweden.
- 700 1_
- $a Hora, Milan $u Department of Urology, Faculty Hospital and Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
- 700 1_
- $a Kuczyk, Markus A $u Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
- 700 1_
- $a Kuusk, Teele $u Department of Urology, Royal Free Hospital, Pond Street, London, UK.
- 700 1_
- $a Lam, Thomas B $u Academic Urology Unit, University of Aberdeen, Aberdeen, UK; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK.
- 700 1_
- $a Marconi, Lorenzo $u Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
- 700 1_
- $a Merseburger, Axel S $u Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
- 700 1_
- $a Powles, Thomas $u The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK.
- 700 1_
- $a Staehler, Michael $u Department of Urology, Ludwig-Maximilians University, Munich, Germany.
- 700 1_
- $a Tahbaz, Rana $u Department of Urology, University Hospital Hamburg Eppendorf, Hamburg, Germany.
- 700 1_
- $a Volpe, Alessandro $u Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.
- 700 1_
- $a Bex, Axel $u The Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 75, č. 5 (2019), s. 799-810
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30803729 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200114083644 $b ABA008
- 999 __
- $a ok $b bmc $g 1483237 $s 1083641
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 75 $c 5 $d 799-810 $e 20190223 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20200109
